Company Overview
Snapshot
Founded in April 2018 by Dr. Ariel Katz and Michael Brandwein, MyOr operates with 11–50 employees. The company has secured funding across two rounds from five investors, with its latest funding round in August 2022.
Business overview
MyOr develops noninvasive monitoring technologies that leverage data-driven artificial intelligence to predict and prevent chronic conditions. The company's AI-driven platform is designed to predict and mitigate the risk of food allergies, eczema, and related conditions. MyOr promotes evidence-based practices and nutrition strategies to improve health outcomes, empowering healthcare providers and caregivers with personalized solutions to eliminate preventable conditions. The company operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, patient engagement, and medical decision support, serving consumers, particularly children, and healthcare providers.
Strategic signal
In October 2023, MyOr Diagnostics was recognized with the prestigious BNEW Prize for Best New Health Startup. This award highlights the company's innovative approach and validates its potential to significantly impact the health tech industry, signaling strong market recognition and future growth prospects for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is MyOr's core focus?
- MyOr focuses on preventive healthcare for children, utilizing noninvasive monitoring technologies and AI to predict and prevent chronic conditions such as food allergies and eczema.
- When was MyOr founded and by whom?
- MyOr was founded in April 2018 by Dr. Ariel Katz and Michael Brandwein.
- What was a significant recent achievement for MyOr?
- In October 2023, MyOr Diagnostics won the prestigious BNEW Prize for Best New Health Startup, recognizing its innovative contributions to healthcare.
- What is MyOr's approach to preventing childhood conditions?
- MyOr employs an AI-driven platform to predict and mitigate the risk of conditions like food allergies and eczema, supported by a network of nutrition experts to educate parents on nutrition strategies.
- Has MyOr engaged in US commercialization efforts?
- In October 2020, MyOr began US commercialization of its platform aimed at preventing allergic conditions.